Denali Therapeutics
DNLI
DNLI
187 hedge funds and large institutions have $2.73B invested in Denali Therapeutics in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 72 increasing their positions, 57 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
4.75% more ownership
Funds ownership: 70.64% → 75.39% (+4.7%)
3% less capital invested
Capital invested by funds: $2.8B → $2.73B (-$71.3M)
1% less funds holding
Funds holding: 189 → 187 (-2)
Holders
187
Holding in Top 10
3
Calls
$1.82M
Puts
$561K
Top Buyers
| 1 | +$152M | |
| 2 | +$19.6M | |
| 3 | +$19M | |
| 4 |
BlackRock
New York
|
+$17.6M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$14.7M |
Top Sellers
| 1 | -$19.5M | |
| 2 | -$13.1M | |
| 3 | -$11.2M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.22M |
| 5 |
Morgan Stanley
New York
|
-$8.32M |